|DB00188||Bortezomib||For treatment of multiple myeloma in patients who have not been successfully treated with at least two previous therapies.|
|DB01104||Sertraline||For the management of major depressive disorder (MDD), posttraumatic stress disorder (PTSD), obsessive-compulsive disorder (OCD), panic disorder (PD) with or without agoraphobia, premenstrual dysphoric disorder (PMDD), and social anxiety disorder (SAD) [FDA Label].
It may be used for premature ejaculation and vascular headaches as off-label indications. |
|DB01171||Moclobemide||For the treatment of major depressive disorder and bipolar disorder [A31901].|
|DB00622||Nicardipine||Used for the management of patients with chronic stable angina and for the treatment of hypertension.|
|DB00625||Efavirenz||For use in combination treatment of HIV infection (AIDS)|
|DB00745||Modafinil||To improve wakefulness in patients with excessive daytime sleepiness (EDS) associated with narcolepsy.|
|DB06413||Armodafinil||Investigated for use/treatment in sleep disorders, obstructive sleep apnea, schizophrenia and schizoaffective disorders, depression, and bipolar disorders.|
|DB08933||Luliconazole||Luliconazole is indicated in adults aged 18 years and older for the topical treatment of fungal infections caused by Trichophyton rubrum and Epidermophyton floccosum, specifically tinea pedis, cruris, and corporis.
|DB09119||Eslicarbazepine acetate||Eslicarbazepine acetate is indicated as adjunctive therapy in the treatment of partial-onset seizures that are not adequately controlled with conventional therapy in epileptic patients. |
|DB05812||Abiraterone||Used in combination with prednisone for the treatment of metastatic, castration-resistant prostate cancer. |
|DB09120||Zucapsaicin||Indicated to be used in conjunction with oral COX-2 inhibitors or NSAIDs for the relief of severe pain in adult patients with osteoarthritis of the knee, not controlled with oral COX-2 inhibitors or NSAIDs alone, for a duration of no more than three months. |